Naslov
Semaglutide-eye-catching results Cigrovski Berkovic M, Strollo F. Semaglutide-eye- catching results. World J Diabetes 2023; 14(4): 424-434 [DOI: 10.4239/wjd.v14.i4.424]

Autori
Cigrovski Berkovic, Maja ; Strollo, Felice

Izvornik
World Journal of Diabetes (1948-9358) 14 (2023), 4; 424-434

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni

Ključne riječi
Glucagon-like peptide-1 receptor agonists ; Semaglutide ; Diabetic retinopathy ; Microvascular complications ; Cardiovascular benefit ; Rehabilitation

Sažetak
Semaglutide is a glucagon-like peptide-1 receptor agonist used either orally every day or subcutaneously once a week for the treatment of type 2 diabetes mellitus and, more recently, at higher doses, for the treatment of obesity. Both diseases are reaching epidemic proportions and often coexist, posing patients with a high risk for cardiovascular disease and death. Therefore, an agent such as semaglutide, which offers clinically significant weight loss and cardiovascular benefits, is essential and will be increasingly used in high- risk patients. However, during the SUSTAIN clinical trial program (Semaglutide Unabated Sustainability in treatment of type 2 diabetes), a safety issue concerning the progression and worsening of diabetic retinopathy emerged. The existing explanation so far mainly supports the role of the magnitude and speed of HbA1c reduction, a phenomenon also associated with insulin treatment and bariatric surgery. Whether and to which extent the effect is direct is still a matter of debate and an intriguing topic to investigate for suitable preventative and rehabilitative purposes. In this minireview, we will summarize the available data and suggest guidelines for a comprehensive semaglutide clinical utilization until new evidence becomes available.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA